Form 4: Atea Pharmaceuticals Director Polly A. Murphy Reports Stock Transaction
SEC Form 4 Filing
Director Polly A. Murphy reports a transaction involving Atea Pharmaceuticals' common stock and restricted stock units.
Summary
- On June 16, 2024, Polly A. Murphy, a director of Atea Pharmaceuticals, Inc. [AVIR], reported a transaction.
- The transaction involved the conversion of 33,150 restricted stock units into common stock.
- Following the reported transaction, Murphy directly owns 56,445 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the director's holdings.
Key Dates
| Date | Description |
|---|---|
| 06/16/2024 | Date of transaction: conversion of restricted stock units to common stock |
| 06/18/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.